Stay updated on SubQ Daratumumab in High-Risk Smoldering Multiple Myeloma Clinical Trial
Sign up to get notified when there's something new on the SubQ Daratumumab in High-Risk Smoldering Multiple Myeloma Clinical Trial page.

Latest updates to the SubQ Daratumumab in High-Risk Smoldering Multiple Myeloma Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedAdded Revision: v3.4.2 to the history; removed the older site-wide notices including the lapse in government funding message and Revision: v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check21 days agoChange DetectedA new 2026-01-30 version entry was added with a Study Status change and Revision: v3.4.1, and the prior 2025-12-23 entry (Revision: v3.4.0) was removed.SummaryDifference0.5%

- Check28 days agoChange DetectedThe record history page now shows a glossary toggle and uses green/red highlights to distinguish additions and deletions, with an updated revision label (v3.4.0). The No FEAR Act data text was removed in this update.SummaryDifference0.4%

- Check35 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4, indicating a minor site revision with no visible changes to study data or page functionality. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check57 days agoChange DetectedAdded entries for Results Posted, More Information, Adverse Events, Outcome Measures (Results), Baseline Characteristics, Participant Flow, and Document Section under the Study Record History dated 2025-12-23. Removed the 'Results Submitted' entry dated 2025-12-08.SummaryDifference0.5%

- Check64 days agoChange DetectedRevision: v3.3.3 was added to the page footer, and the HHS Vulnerability Disclosure link and Revision: v3.3.2 were removed. This appears to be a routine maintenance update that does not affect trial details or user actions.SummaryDifference0.1%

Stay in the know with updates to SubQ Daratumumab in High-Risk Smoldering Multiple Myeloma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SubQ Daratumumab in High-Risk Smoldering Multiple Myeloma Clinical Trial page.